当前位置:
X-MOL 学术
›
Cancer Cell
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy.
Cancer Cell ( IF 48.8 ) Pub Date : 2020-06-08 , DOI: 10.1016/j.ccell.2020.05.012 Jack D Chan 1 , Paul A Beavis 1 , Phillip K Darcy 2
中文翻译:
p38激酶:驱动有效T细胞用于过继免疫疗法的关键靶标。
更新日期:2020-06-08
Cancer Cell ( IF 48.8 ) Pub Date : 2020-06-08 , DOI: 10.1016/j.ccell.2020.05.012 Jack D Chan 1 , Paul A Beavis 1 , Phillip K Darcy 2
Affiliation
In this issue of Cancer Cell, Gurusamy et al. use a CRISPR-Cas9 screening approach to demonstrate that deletion of p38 increases multiple phenotypic qualities of effective anti-tumor T cells. Preconditioning T cells with a p38 inhibitor enhances anti-tumor efficacy of adoptive immunotherapy.
中文翻译:
p38激酶:驱动有效T细胞用于过继免疫疗法的关键靶标。
在本期《癌细胞》中,Gurusamy等人。使用CRISPR-Cas9筛选方法来证明p38的缺失增加了有效抗肿瘤T细胞的多种表型质量。用p38抑制剂预处理T细胞可增强过继免疫疗法的抗肿瘤功效。